Quantum Cyber N.V. (QUCY) SEC filings document a Nasdaq-listed issuer whose public record includes both its former Mainz Biomed N.V. identity and its newer autonomous defense technology focus. The company’s quarterly reports and 8-K filings are important because they describe material agreements, license arrangements, property acquisition activity, capital structure matters, governance items, and operating and financial results.
For QUCY, quarterly reports can show how the company reports expenses, liabilities, share issuance, and historical operating results. Recent quarterly disclosure describes the exclusive LightShift license for quantum photonic array technology, the related accounting treatment, and the company’s issued ordinary shares. Earlier quarterly disclosure also discusses ColoAlert sales and the wind down of the prior colorectal cancer screening sales and marketing team.
Material 8-K filings are especially relevant for Quantum Cyber because they have covered the Project LightShift intellectual property license, an amendment involving BP United manufacturing and consulting services, termination of an at-the-market issuance sales agreement, a change in independent registered public accounting firm, investor presentation materials, and the Bridgeport property acquisition involving Quantum Drones Corporation and Arcade Realty LLC.
Annual reports, proxy statements, and Form 4 insider transaction reports, when available, add context on risk factors, governance, executive compensation, ownership changes, and insider trading activity. Plain-language filing summaries can help readers separate core disclosures from legal formatting, with particular attention to 10-Q reports, 10-K annual reports, Form 4 transactions, and 8-K material event filings tied to QUCY’s defense technology and manufacturing strategy.
O'Rourke Peter reported acquisition or exercise transactions in this Form 4 filing.
Quantum Cyber N.V. director Peter O'Rourke received a grant of 191,860 stock options on July 22, 2026, each exercisable at 1.1400 per share for Ordinary Shares and expiring August 3, 2036. The amended report corrects the transaction date, option and underlying share quantities, and post-transaction beneficial ownership, and now shows 191,860 derivative securities held directly. The options vest in eighteen substantially equal installments on each monthly anniversary of the grant date, contingent on O'Rourke continuing to provide services.
Quantum Cyber N.V. director Natan David received a grant of Stock Options (Right to Buy) covering 191,860 Ordinary Shares at an exercise price of 1.1400 per share, expiring 2036-08-03. The options vest in eighteen substantially equal monthly installments, contingent on continued service, and the corrected report shows 191,860 options beneficially owned after the transaction.
Quantum Cyber N.V. filed an amended Form 4 reporting that Chief Financial Officer William J. Caragol received a grant of 212,500 stock options to purchase Ordinary Shares at an exercise price of $1.14 per share. The options expire on 2036-08-03 and vest in eighteen substantially equal monthly installments from the grant date, contingent on continued service; the amendment corrects the previously reported transaction date.
Quantum Cyber N.V. director Louis R. Buffalino received a grant of 425,000 Stock Options (Right to Buy) on July 22, 2026. Each option is exercisable for one Ordinary Share at an exercise price of $1.14 per share and expires on August 3, 2036. The amended report corrects the date of the reported transaction. The Stock Options vest in eighteen substantially equal monthly installments from the grant date, subject to his continued service, leaving 425,000 options reported as held directly after the grant.
Quantum Cyber N.V. director Ben-Tzvi Avraham received a grant of 112,859 Ordinary Shares on July 22, 2026 at $0.00 per share, increasing his direct holdings to 252,000 shares. This amended Form 4 corrects the originally reported transaction date, shares acquired, and post-transaction beneficial ownership.
Quantum Cyber N.V. director Ben-Tzvi Avraham reported receiving a grant of 112,259 Ordinary Shares on July 31, 2026, at $0.0000 per share. After this grant, he directly owns 251,400 Ordinary Shares. The transaction is classified as a grant, award, or other acquisition and was not made under a Rule 10b5-1 trading plan.
O'Rourke Peter reported acquisition or exercise transactions in this Form 4 filing.
Quantum Cyber N.V. director O'Rourke Peter received a grant of 190,840 stock options on 2026-07-31, each exercisable at 1.1400 per share into Ordinary Shares and expiring on 2036-08-03. The options vest in eighteen substantially equal monthly installments while he continues providing services, and this grant brings his reported derivative holdings to 190,840 options.
Quantum Cyber N.V. granted director Natan David stock options on July 31, 2026 to acquire 190,840 ordinary shares at an exercise price of $1.1400 per share. The options expire on August 3, 2036 and vest in eighteen substantially equal monthly installments, conditioned on his continued service. Following this grant, he holds 190,840 stock options directly.
Quantum Cyber N.V. reported that Chief Financial Officer William J. Caragol received a grant of stock options covering 212,500 Ordinary Shares at an exercise price of $1.1400 per share, expiring on 2036-08-03. The options vest in eighteen substantially equal monthly installments, conditioned on his continued service.
Quantum Cyber N.V. reported that director Louis R. Buffalino received a grant of 425,000 stock options on 2026-07-31. These options allow him to acquire Ordinary Shares at an exercise price of $1.1400 per share and expire on 2036-08-03. Following the grant, he held all 425,000 options directly. According to the terms, the options vest in eighteen substantially equal monthly installments, provided he continues to provide services through each vesting date.